The UK pharma group fought Pfizer's $120 billion bid by promising growth. But its defence has been aided most by U.S. curbs on tax-driven M&A, says Reuters Breakingviews.
01:34
01:09
01:17
01:19
01:34
01:53
02:21
01:39
02:38
02:16
01:26
00:52
00:33
01:29
01:20
01:03
00:59
01:01
01:32
01:34
01:29
01:59
01:05
01:26
00:59
01:15
01:12
01:18
00:44
01:50
01:17
01:26
00:50
01:32
01:33
00:51
01:43
01:11
01:45
01:48
01:19
01:03
01:00
00:45
00:46
00:57
02:05
01:25
01:46
01:04
02:03
02:16
01:18
01:13
00:29
02:05
00:47
01:11
01:20
01:30
02:16
01:39
01:56
00:33
01:32
02:08
01:50
01:58
01:41
01:32
01:31
02:00
01:01
01:55
02:30
01:32
01:28
02:24
01:38
01:21
01:51
01:22
01:05
01:06
01:30
01:11
01:17
01:12
01:52
00:50
01:13
01:34
02:18
01:24
01:12
01:12
00:51
01:05
01:09
01:02
01:01
01:32
01:24
01:40
01:00
01:31
01:15
02:05
01:20
01:03
01:16
01:50
00:53
03:21
01:33
01:21
01:22
02:18
01:16
01:42